President Trump on Thursday sent letters to 17 of the world’s biggest drugmakers demanding that they reduce some of their U.S. prices to the much lower levels they charge other wealthy countries by ...

Tempus AI's 10% dip reveals an opportunity as Q2 estimates are poised to exceed expectations, fueled by strong deals and ...

Looking for sleep well at night stocks? Read about three stocks that could deliver strong return potential over the next five ...

Ionis Pharmaceuticals IONS reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, significantly beating the Zacks Consensus Estimate of 27 cents. In the year-ago period, the ...

Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

While value has outperformed growth in Europe over the past five years, Europe now represents less than half of equity market ...

A formal trade agreement between the US and EU introduces a 15% tariff on most EU exports, including pharmaceuticals, ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca PLC (NASDAQ:AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) announced ...